In a significant milestone for neural engineering and ophthalmology, Science Corporation has unveiled compelling long-term data from its pivotal PRIMAvera study. The findings demonstrate that the PRIMA subretinal implant, when paired with specialized visual-processing glasses, provides durable and escalating vision restoration for patients suffering from geographic atrophy (GA), a severe and debilitating form of age-related macular degeneration (AMD).
As the global medical community grapples with a growing population of patients facing central vision loss, these results offer a beacon of hope. With the data now presented to the international stage at the EURETINA Congress in Vienna, the focus shifts to the United States, where the US Food and Drug Administration (FDA) is currently evaluating the device for market entry.
The PRIMAvera Study: A Three-Year Benchmark
The PRIMAvera clinical trial (NCT04676854) was designed to evaluate the safety and efficacy of the PRIMA system. The device functions as a subretinal photovoltaic implant, surgically positioned behind the retina in the area where the patient’s natural photoreceptors have degenerated due to GA.
The system works through a sophisticated synergy between the implant and a pair of wearable glasses. The glasses capture visual information and project near-infrared light onto the implant, which then mimics the activity of the lost photoreceptors. By stimulating the remaining healthy cells, the device transmits visual signals to the brain, effectively bypassing the damaged biological components of the eye.
The 36-month data set is particularly notable for its consistency and improvement over time. While many medical interventions see a plateau in efficacy, the PRIMA system showed a continued trajectory of improvement.
Supporting Data: Evidence of Sustained Visual Recovery
The clinical findings, which track patient progress from the 12-month mark to the 36-month conclusion of the study, are robust. At the 36-month follow-up, participants demonstrated an average improvement of 29 letters on a standard ETDRS eye test chart—a visual gain equivalent to nearly six lines of text.
This represents a statistically significant improvement over the 24.5-letter average recorded at the 12-month mark, suggesting that patients not only adapt to the device but potentially optimize their visual processing over time. Furthermore, the efficacy-evaluable cohort showed that 14 out of 18 patients achieved a minimum gain of 15 letters at three years, a threshold typically considered clinically meaningful by regulatory bodies.
Importantly, this gain was achieved without compromising the patients’ existing natural peripheral vision, which remained stable throughout the trial duration. This stability is a critical success factor for patients who rely on remaining retinal function for navigation and daily tasks.
Safety Profile and Longitudinal Stability
For any implantable neural device, the safety profile is as critical as its efficacy. The PRIMAvera study provided granular insights into the long-term biological response to the device. Researchers reported no new safety signals between the 12-month and 36-month intervals.
While serious adverse events (AEs) were documented in the study, they were concentrated primarily in the initial six-month post-surgical period, consistent with standard recovery expectations for complex ocular surgery. Only three AEs were reported after the 12-month mark, and notably, none of these incidents were attributed to the PRIMA implant itself. This suggests that the device is well-tolerated by the retinal tissue over the long term, mitigating concerns regarding chronic inflammation or mechanical degradation of the retina.
Chronology of Development and Regulatory Trajectory
The journey of the PRIMA device reflects the accelerating pace of innovation in the ophthalmic sector. Science Corporation’s development strategy has been characterized by a measured, step-wise approach to regulatory approval:
- Early Development: Initial prototyping and feasibility studies established the viability of the subretinal photovoltaic approach.
- European and UK Market Entry: The PRIMA system successfully secured regulatory pathways in Europe and the United Kingdom, where it is currently available to patients indicated for GA secondary to AMD.
- The PRIMAvera Study (2020–2026): Launched in late 2020, the trial provided the longitudinal data necessary to prove the device’s durability.
- EURETINA Congress (October 2026): The formal presentation of the 36-month data in Vienna marked the first global unveiling of these long-term results to the specialized retina community.
- Current FDA Review: The company is currently engaged in the rigorous review process with the US FDA, a move that could potentially open the world’s largest medical device market to this technology.
Implications for the Future of Ophthalmology
The implications of these results extend beyond individual patient outcomes. Geographic atrophy affects an estimated five to eight million people worldwide. As the global population ages, the prevalence of AMD-related blindness is projected to rise, placing a massive burden on healthcare systems and individual quality of life.
The Competitive Landscape
While Science Corporation is currently leading with this specific subretinal approach, the field is becoming increasingly competitive. Other innovators, such as LumiThera, have recently gained FDA authorization for their Valeda Light Delivery System. However, the mechanism of action for Valeda—which uses multi-wavelength LED lights to stimulate cellular repair—differs significantly from the prosthetic, image-projecting nature of PRIMA. The availability of diverse treatment modalities represents a "golden age" for GA treatment, where different stages and types of the disease can be managed with tailored technological solutions.
Market Growth and Economic Impact
According to industry analysis by GlobalData, the ophthalmic devices market is on a robust growth trajectory. The market is projected to expand at a compound annual growth rate (CAGR) of 4.7%, reaching a total valuation of nearly $15 billion by 2035. This growth is driven by both the increasing incidence of degenerative eye diseases and the rapid adoption of "smart" medical devices that interface directly with the human nervous system.
The Patient Experience
For the patient, the ability to read letters on a chart is more than a clinical metric; it is a gateway to independence. Central vision loss is often cited as one of the most debilitating conditions, stripping individuals of the ability to read, drive, or recognize faces. By restoring a measurable degree of reading acuity, the PRIMA system addresses a fundamental deficit in current ophthalmological care.
Official Perspectives and Looking Ahead
While Science Corporation has yet to release a definitive timeline for a US launch, the optimism surrounding their data is palpable. The success of the PRIMAvera study positions the company as a leader in "neural engineering," a field that blends micro-electronics with biological systems to restore lost sensory function.
Industry experts note that the consistency of the results—particularly the increase in letter recognition from year one to year three—is a "compelling narrative" for regulators. Typically, medical devices in this category might see a plateau; the fact that PRIMA patients showed continued improvement suggests a potential for neuroplasticity or improved patient mastery of the device interface over time.
As the FDA completes its review, the medical community will be watching closely. Should the PRIMA system be approved, it will likely represent a paradigm shift in how we treat late-stage retinal degeneration, moving the standard of care from passive monitoring and supportive care to active, device-mediated restoration of visual function.
Conclusion
The 36-month data from the PRIMAvera study represents a landmark moment for Science Corporation and the millions of patients living with the shadows of geographic atrophy. By proving that a subretinal device can be both safe and increasingly effective over three years, the company has cleared one of the highest hurdles in medical technology development.
As the industry looks toward 2035 and beyond, the integration of neural engineering into clinical ophthalmology seems inevitable. The PRIMA system, with its combination of cutting-edge hardware and sophisticated light-projection technology, stands as a testament to the power of human ingenuity to illuminate the world for those who have lost the ability to see it. Whether in the clinics of Europe or the future medical centers of the United States, the trajectory of this device suggests that the definition of "irreversible" vision loss is currently being rewritten.
About the Author
